Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
Journal of Virology
|
February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates
Anne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
Plos Neglected Tropical Diseases
|
August 11, 2011
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial
Anna P Durbin, Stephen S Whitehead, Donna Shaffer, et al.
Journal of Virology
|
December 28, 2002
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic
Mario H Skiadopoulos, Alexander C Schmidt, Jeffrey M Riggs, et al.
Vaccine
|
October 28, 2009
A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates
Emmalene J Bartlett, Ann-Marie Cruz, Jim Boonyaratanakornkit, et al.
PLOS Global Public Health
|
November 8, 2023
Data-driven epidemiologic approach to conducting site feasibility for a global phase III tuberculosis vaccine clinical trial
Wai-Ling Mui, Falgunee K Parekh, Ashley S Tseng, et al.
Virology
|
December 9, 2009
Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates
Anne Schaap-Nutt, Christopher D'Angelo, Margaret A Scull, et al.
Journal of the Pediatric Infectious Diseases Society
|
November 20, 2015
Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children
Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, et al.
Vaccine
|
June 10, 2026
The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design
Alemnew F Dagnew, Alexander C Schmidt, Amy Cinar, et al.
Vaccine
|
May 12, 2026
Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine
Alemnew F Dagnew, Robert Noble, Amy Cinar, et al.
The American Journal of Tropical Medicine and Hygiene
|
November 5, 2008
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity
Julie H McArthur, Anna P Durbin, Jennifer A Marron, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
Journal of Virology
|
February 4, 2011
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates
Anne Schaap-Nutt, Caraline Higgins, Emerito Amaro-Carambot, et al.
Plos Neglected Tropical Diseases
|
August 11, 2011
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial
Anna P Durbin, Stephen S Whitehead, Donna Shaffer, et al.
Journal of Virology
|
December 28, 2002
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic
Mario H Skiadopoulos, Alexander C Schmidt, Jeffrey M Riggs, et al.
Vaccine
|
October 28, 2009
A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates
Emmalene J Bartlett, Ann-Marie Cruz, Jim Boonyaratanakornkit, et al.
PLOS Global Public Health
|
November 8, 2023
Data-driven epidemiologic approach to conducting site feasibility for a global phase III tuberculosis vaccine clinical trial
Wai-Ling Mui, Falgunee K Parekh, Ashley S Tseng, et al.
Virology
|
December 9, 2009
Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates
Anne Schaap-Nutt, Christopher D'Angelo, Margaret A Scull, et al.
Journal of the Pediatric Infectious Diseases Society
|
November 20, 2015
Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children
Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, et al.
Vaccine
|
June 10, 2026
The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design
Alemnew F Dagnew, Alexander C Schmidt, Amy Cinar, et al.
Vaccine
|
May 12, 2026
Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine
Alemnew F Dagnew, Robert Noble, Amy Cinar, et al.
The American Journal of Tropical Medicine and Hygiene
|
November 5, 2008
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity
Julie H McArthur, Anna P Durbin, Jennifer A Marron, et al.
Page
of 6